Vinicio Napoli, 1 Raffaella Berchiolli, 2 Maria Chiara Carboncini, 3 Ferdinando Sartucci, Associate Professor, 4 Michele Marconi, 2 Tommaso Bocci, 4 Orsola Perrone, 1 Nicola Mannoni, 4 Claudia Congestrı`, 4 Roberta Benedetti, 3 Riccardo Morganti, 5 Davide Caramella, Full Professor, 6 Roberto Cioni, 1 and Mauro Ferrari, Full Professor 2 Pisa, Italy
Background: Venous percutaneous transluminal angioplasty (vPTA) in patients with multiple sclerosis (MS) and chronic cerebrospinal venous insufﬁciency (CCSVI) have shown contradictory results. The aim of the study is to evaluate the efﬁcacy of the procedure in a randomized wait list control study.
Methods: 66 adults with neurologist-conﬁrmed diagnosis of MS and sonographic diagnosis of CCSVI were allocated into vPTA-yes group (n ¼ 31) or vPTA-not group (n ¼ 35, control group). vPTA was performed immediately 15 days after randomization in the PTA-yes group and 6 months later in the control group. Evoked potentials (EPs), clinical-functional measures (CFMs), and upper limb kinematic measures (ULKMs) were measured at baseline (T0) and six months after in both groups, just before the venous angioplasty in the vPTA-not group (T1).
Results: Comparing the vPTA-yes and vPTA-not group, the CFM-derived composite functional outcome showed 11 (37%) versus 7 (20%) improved, 1 (3%) versus 3 (8%) stable, 0 versus 7 (20%) worsened, and 19 (61%) versus 18 (51%) mixed patients (c 2 ¼ 8.71, df ¼ 3, P ¼ 0.03). Unadjusted and adjusted (for baseline confounding variables) odds ratio at 95% conﬁdence interval were, respectively, 1.93 (1.3-2.8), P value 0.0007, and 1.85 (1.2-1.7), P value 0.002. EPand ULKM-derived composite functional outcome showed no signiﬁcant difference between the two groups.
Conclusions: Venous angioplasty can positively impact a few CFMs especially for the quality of life but achieving disability improvement is unlikely.